MSOS stock forecast, quote, news & analysis

Key Takeaways

• MSOS provides actively managed exposure exclusively to U.S. cannabis companies deriving at least 50% of revenue from marijuana and hemp businesses, utilizing equity swaps for efficiency.
• Highly concentrated portfolio with top holdings including Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries, representing over 65% of assets and nearly 98% in multi-state operators.
• Net expense ratio of 0.78%, reflecting active management costs in a thematic space with daily portfolio adjustments rather than fixed rebalancing.
• Positioned amid ongoing federal rescheduling debates and state-level expansions, offering potential from policy shifts but exposed to regulatory, tax (Section 280E), and market oversupply risks.
• Recent volatility tied to reform expectations highlights the ETF's sensitivity to capital flows and sector catalysts like pricing pressures and consolidation.
• Liquidity challenges in OTC-traded holdings underscore the need for monitoring trading volumes and swap counterparty risks.

AdvisorShares Pure US Cannabis ETF (MSOS) Overview

The AdvisorShares Pure US Cannabis ETF (MSOS) is an actively managed exchange-traded fund launched on September 1, 2020, seeking long-term capital appreciation. Under normal circumstances, it invests at least 80% of its net assets in securities of U.S. companies deriving at least 50% of their revenue from the marijuana and hemp business, including derivatives like equity swaps that exhibit similar economic characteristics.

MSOS holds approximately 66 positions, including equities and swaps, with a heavy concentration in multi-state operators (MSOs). As of early March 2026, top holdings include Curaleaf Holdings Inc. swap (CURLF, 24.49%), Trulieve Cannabis Corp. swap (TCNNF, 21.96%), and Green Thumb Industries Inc. swap (GTBIF, 21.36%), followed by Glass House Brands swap (GLASF, 7.68%), Cresco Labs Inc. swap (CRLBF, 6.57%), and Verano Holdings Corp. swap (VRNOF, 6.51%). These top positions account for over 88% of the portfolio.

Sector allocations emphasize MSOs at 98%, with minor exposure to healthcare (0.5%) and agriculture (1.6%). The net expense ratio stands at 0.78% (gross 0.81%), supported by a fee waiver. Daily active management enables opportunistic adjustments to market dynamics, distinguishing it from passive index-tracking peers.

Industry and Thematic Landscape

The U.S. cannabis sector centers on multi-state operators navigating a patchwork of 24 adult-use and 39 medical markets as of 2026. Structural growth drivers include rising social acceptance, state expansions like New York's maturing retail footprint, and potential federal rescheduling from Schedule I to III, which could alleviate Section 280E tax burdens prohibiting expense deductions.

Capital flows remain constrained by federal illegality, limiting banking access and favoring private equity or high-yield debt, though rescheduling optimism has spurred selective inflows. Macroeconomic factors such as inflation-driven pricing compression and oversupply in mature markets like California pose challenges, with 2025 revenues projected to dip slightly to $29 billion before rebounding toward $47 billion by year-end 2026.

Regulatory developments include intoxicating hemp restrictions via the 2025 Farm Bill and state ballot initiatives. Risks encompass enforcement disparities, competition from illicit channels, and consolidation pressures amid $3 billion in maturing debt.

Performance and Positioning Snapshot

In recent market cycles, MSOS has exhibited sharp volatility reflective of cannabis sector dynamics. Year-to-date through early 2026, the ETF posted modest gains amid broader equity rotations, though quarterly swings tied to rescheduling headlines—such as executive orders and policy signals—drove double-digit surges followed by pullbacks.

Over the past year, MSOS outperformed broader cannabis benchmarks, buoyed by operational resilience among top MSOs amid earnings seasons highlighting cost efficiencies. Sector rotation from high-growth tech toward value-oriented cyclicals has intermittently supported exposure, while commodity-like price pressures tempered gains. Geopolitical stability and rate expectations have indirectly aided by stabilizing capital costs for debt-heavy operators.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI-driven trading bots under prevailing market conditions. Tickeron provides hundreds of AI bots scanning thousands of tickers across strategies like trend-following, mean reversion, and momentum, with timeframes from intraday to long-term. Only the strongest current performers—often displaying win rates above 60% and average returns in the double digits—are curated here, based on real-time backtested and live metrics. Users can explore bots tailored to specific assets, including ETFs like MSOS, and deploy them via integrated brokerage links. This section offers retail and professional investors transparent insights into algorithmic edges. Visit the Trending AI Robots page to evaluate and activate high-conviction signals today.

2026 Outlook and Key Factors to Monitor

Looking to 2026, the U.S. cannabis landscape holds structural tailwinds from rescheduling implementation, potentially easing 280E taxes and unlocking institutional capital flows estimated at billions. State-level adult-use ballot measures in Florida and Pennsylvania could expand addressable markets, bolstering MSO revenues amid projected industry growth to $47 billion.

Macro risks include persistent oversupply in fragmented states, inflationary pressures on cultivation costs, and delayed banking reforms under varying policy regimes. Earnings cycles for leading MSOs like Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries will highlight margin expansion via vertical integration and export potential to international markets.

Competitive pressures may accelerate M&A consolidation, favoring cash-rich operators while challenging smaller players. MSOS’s active management and 0.78% expense ratio position it to navigate these shifts, though swap exposures warrant scrutiny for counterparty risks. Investors should track federal DEA timelines, state licensing velocities, wholesale pricing trends, and debt maturities exceeding $3 billion, balancing reform optimism against execution hurdles in a maturing sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations